These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 38399608)

  • 1. Current Role and Future Prospects of Positron Emission Tomography (PET)/Computed Tomography (CT) in the Management of Breast Cancer.
    Robson N; Thekkinkattil DK
    Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artificial Intelligence in Breast Cancer: A Systematic Review on PET Imaging Clinical Applications.
    Alongi P; Rovera G; Stracuzzi F; Popescu CE; Minutoli F; Arnone G; Baldari S; Deandreis D; Caobelli F
    Curr Med Imaging; 2023; 19(8):832-843. PubMed ID: 36703586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Present and future role of FDG-PET/CT imaging in the management of breast cancer.
    Kitajima K; Miyoshi Y
    Jpn J Radiol; 2016 Mar; 34(3):167-80. PubMed ID: 26733340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline FDG PET-CT imaging is necessary for newly diagnosed inflammatory breast cancer patients: a narrative review.
    Patel MM; Le-Petross HT
    Chin Clin Oncol; 2021 Dec; 10(6):56. PubMed ID: 34806397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The lung cancers: staging and response, CT,
    Owens C; Hindocha S; Lee R; Millard T; Sharma B
    Br J Radiol; 2023 Aug; 96(1148):20220339. PubMed ID: 37097296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of
    Dayes IS; Metser U; Hodgson N; Parpia S; Eisen AF; George R; Blanchette P; Cil TD; Arnaout A; Chan A; Levine MN
    J Clin Oncol; 2023 Aug; 41(23):3909-3916. PubMed ID: 37235845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
    Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
    Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. F-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography Has High Diagnostic Value for Pelvic and Distant Staging in Patients with High-risk Penile Carcinoma.
    Ottenhof SR; Djajadiningrat RS; Versleijen MWJ; Donswijk ML; van der Noort V; Brouwer OR; Graafland NM; Vegt E; Horenblas S
    Eur Urol Focus; 2022 Jan; 8(1):98-104. PubMed ID: 33685842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting the accuracy of
    Kutluturk K; Simsek A; Comak A; Gonultas F; Unal B; Kekilli E
    Niger J Clin Pract; 2019 Jan; 22(1):63-68. PubMed ID: 30666022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI fused with prone FDG PET/CT improves the primary tumour staging of patients with breast cancer.
    Garcia-Velloso MJ; Ribelles MJ; Rodriguez M; Fernandez-Montero A; Sancho L; Prieto E; Santisteban M; Rodriguez-Spiteri N; Idoate MA; Martinez-Regueira F; Elizalde A; Pina LJ
    Eur Radiol; 2017 Aug; 27(8):3190-3198. PubMed ID: 28004161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ¹⁸F-FDG PET/CT for Staging and Restaging of Breast Cancer.
    Groheux D; Cochet A; Humbert O; Alberini JL; Hindié E; Mankoff D
    J Nucl Med; 2016 Feb; 57 Suppl 1():17S-26S. PubMed ID: 26834096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of 18F-FDG PET/CT imaging in breast cancer staging.
    Yararbas U; Avci NC; Yeniay L; Argon AM
    Bosn J Basic Med Sci; 2018 Feb; 18(1):72-79. PubMed ID: 28763628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of FDG PET/CT in the clinical management of breast cancer.
    Groheux D; Espié M; Giacchetti S; Hindié E
    Radiology; 2013 Feb; 266(2):388-405. PubMed ID: 23220901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG-PET/CT for Primary Staging and Detection of Recurrence of Breast Cancer.
    Groheux D
    Semin Nucl Med; 2022 Sep; 52(5):508-519. PubMed ID: 35636977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Role of Fluorodeoxyglucose PET in Breast Cancer: A History to Current Application.
    Chakraborty D; Basu S; Ulaner GA; Alavi A; Kumar R
    PET Clin; 2018 Jul; 13(3):355-361. PubMed ID: 30100075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advantages and limitations of FDG PET in the follow-up of breast cancer.
    Lind P; Igerc I; Beyer T; Reinprecht P; Hausegger K
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S125-34. PubMed ID: 15085295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning.
    Jacene HA; DiPiro PJ; Bellon J; Hu J; Cheng SC; Warren L; Schlosnagle E; Nakhlis F; Rosenbluth JM; Yeh E; Overmoyer B
    Breast Cancer Res Treat; 2020 Jun; 181(2):383-390. PubMed ID: 32318957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET/CT in high-risk primary breast cancer-a prospective study of stage migration and clinical impact.
    Vogsen M; Jensen JD; Christensen IY; Gerke O; Jylling AMB; Larsen LB; Braad PE; Søe KL; Bille C; Ewertz M; Hildebrandt MG
    Breast Cancer Res Treat; 2021 Jan; 185(1):145-153. PubMed ID: 32920740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorodeoxyglucose positron emission tomography (18F-FDG PET)-computed tomography (CT) in the initial staging of bladder cancer: a single institution experience.
    Shahait M; Abu-Hijlih R; Farkouh A; Obeidat S; Salah S; Abdlkadir AS; Al-Ibraheem A
    J Egypt Natl Canc Inst; 2023 Jul; 35(1):21. PubMed ID: 37455263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.